KEGG   PATHWAY: biu05235
Entry
biu05235                    Pathway                                
Name
PD-L1 expression and PD-1 checkpoint pathway in cancer - Bos indicus (zebu cattle)
Description
Programmed cell death 1 (PD1) and its ligand (PDL1) are key regulatory physiological immune checkpoints that maintain self-tolerance in the organism by regulating the degree of activation of T and B  cells amongst other immune cell types. In solid tumors, the PD-1/PD-L1 inhibitory pathway can be (mis-)used to silence the immune system by increasing the expression of PD-L1 on the tumor cell surface. Up-regulation of PD-L1 is caused by activation of pro-survival pathways MAPK and PI3K/Akt as well as transcriptional factors HIF-1, STAT3 and NF-kappa B. The MAPK and PI3K signalling pathways are activated by gene mutations and growth factors. PD-L1 on tumor cells may then engage the PD-1 receptors resulting in suppression of T-cell mediated immune response. Therapeutic antibodies blocking the PD-1/PD-L1 pathway by targeting PD-L1 or PD-1 are highly effective in rescuing T cell anti-tumor effector functions.
Class
Human Diseases; Cancer: overview
Pathway map
biu05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
biu05235

Organism
Bos indicus (zebu cattle) [GN:biu]
Gene
109565231  HIF1A; hypoxia-inducible factor 1-alpha [KO:K08268]
109559983  EGF; LOW QUALITY PROTEIN: pro-epidermal growth factor [KO:K04357]
109576048  EGFR; epidermal growth factor receptor [KO:K04361] [EC:2.7.10.1]
109560940  GTPase HRas-like [KO:K02833]
109559581  KRAS; GTPase KRas isoform X1 [KO:K07827]
109555890  NRAS; GTPase NRas [KO:K07828]
109576053  RAF1; LOW QUALITY PROTEIN: RAF proto-oncogene serine/threonine-protein kinase [KO:K04366] [EC:2.7.11.1]
109564697  MAP2K1; dual specificity mitogen-activated protein kinase kinase 1 isoform X1 [KO:K04368] [EC:2.7.12.2]
109561751  MAP2K2; dual specificity mitogen-activated protein kinase kinase 2 [KO:K04369] [EC:2.7.12.2]
109578667  MAPK3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
109570973  MAPK1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
109565363  FOS; proto-oncogene c-Fos [KO:K04379]
109556235  JUN; transcription factor AP-1 [KO:K04448]
109566017  EML4; echinoderm microtubule-associated protein-like 4 isoform X1 [KO:K15420]
109565582  ALK; ALK tyrosine kinase receptor [KO:K05119] [EC:2.7.10.1]
109574805  PIK3R1; LOW QUALITY PROTEIN: phosphatidylinositol 3-kinase regulatory subunit alpha [KO:K02649]
109561418  PIK3R2; phosphatidylinositol 3-kinase regulatory subunit beta [KO:K02649]
109556345  phosphatidylinositol 3-kinase regulatory subunit gamma [KO:K02649]
109559805  PIK3CB; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform [KO:K00922] [EC:2.7.1.153]
109570415  PIK3CD; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform [KO:K00922] [EC:2.7.1.153]
109557823  PIK3CA; LOW QUALITY PROTEIN: phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform [KO:K00922] [EC:2.7.1.153]
109552991  PTEN; phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN [KO:K01110] [EC:3.1.3.16 3.1.3.48 3.1.3.67]
109572496  AKT2; RAC-beta serine/threonine-protein kinase [KO:K04456] [EC:2.7.11.1]
109570286  AKT3; RAC-gamma serine/threonine-protein kinase isoform X1 [KO:K04456] [EC:2.7.11.1]
109570401  MTOR; serine/threonine-protein kinase mTOR [KO:K07203] [EC:2.7.11.1]
109554358  RPS6KB2; ribosomal protein S6 kinase beta-2 [KO:K04688] [EC:2.7.11.1]
109573726  RPS6KB1; ribosomal protein S6 kinase beta-1 [KO:K04688] [EC:2.7.11.1]
109553086  CHUK; inhibitor of nuclear factor kappa-B kinase subunit alpha isoform X1 [KO:K04467] [EC:2.7.11.10]
109553353  IKBKB; inhibitor of nuclear factor kappa-B kinase subunit beta [KO:K07209] [EC:2.7.11.10]
109575581  NFKBIA; NF-kappa-B inhibitor alpha [KO:K04734]
109572576  NFKBIB; NF-kappa-B inhibitor beta [KO:K02581]
109577350  NFKBIE; NF-kappa-B inhibitor epsilon [KO:K05872]
109560296  NFKB1; LOW QUALITY PROTEIN: nuclear factor NF-kappa-B p105 subunit [KO:K02580]
109554392  RELA; transcription factor p65 [KO:K04735]
109558719  IFNG; interferon gamma [KO:K04687]
109563984  IFNGR1; interferon gamma receptor 1 [KO:K05132]
109569763  IFNGR2; interferon gamma receptor 2 [KO:K05133]
109556202  JAK1; LOW QUALITY PROTEIN: tyrosine-protein kinase JAK1 [KO:K11217] [EC:2.7.10.2]
109562906  JAK2; tyrosine-protein kinase JAK2 isoform X1 [KO:K04447] [EC:2.7.10.2]
109568771  STAT1; signal transducer and activator of transcription 1-alpha/beta [KO:K11220]
109573817  STAT3; signal transducer and activator of transcription 3 isoform X1 [KO:K04692]
109571498  TLR2; toll-like receptor 2 [KO:K10159]
109563399  TLR4; toll-like receptor 4 isoform X1 [KO:K10160]
109576281  TLR9; toll-like receptor 9 [KO:K10161]
109554591  TIRAP; toll/interleukin-1 receptor domain-containing adapter protein [KO:K05403]
109576356  MYD88; myeloid differentiation primary response protein MyD88 isoform X1 [KO:K04729]
109565970  LOW QUALITY PROTEIN: TNF receptor-associated factor 6-like [KO:K03175] [EC:2.3.2.27]
109577750  NFATC1; nuclear factor of activated T-cells, cytoplasmic 1 isoform X1 [KO:K04446]
109567554  NFATC2; nuclear factor of activated T-cells, cytoplasmic 2 isoform X1 [KO:K17332]
109572084  NFATC3; nuclear factor of activated T-cells, cytoplasmic 3 isoform X1 [KO:K17333]
109561728  TICAM1; TIR domain-containing adapter molecule 1 [KO:K05842]
109564619  TICAM2; TIR domain-containing adapter molecule 2 [KO:K05409]
109562902  CD274; programmed cell death 1 ligand 1 isoform X1 [KO:K06745]
109556613  PDCD1; programmed cell death protein 1 isoform X1 [KO:K06744]
109558908  PTPN6; tyrosine-protein phosphatase non-receptor type 6 isoform X1 [KO:K05697] [EC:3.1.3.48]
109570927  PTPN11; tyrosine-protein phosphatase non-receptor type 11 [KO:K07293] [EC:3.1.3.48]
109570168  tyrosine-protein phosphatase non-receptor type 11-like [KO:K07293] [EC:3.1.3.48]
109565365  BATF; basic leucine zipper transcriptional factor ATF-like [KO:K09034]
109570757  BATF3; basic leucine zipper transcriptional factor ATF-like 3 isoform X1 [KO:K09034]
109554671  BATF2; basic leucine zipper transcriptional factor ATF-like 2 isoform X1 [KO:K09034]
109567333  CSNK2A1; casein kinase II subunit alpha [KO:K03097] [EC:2.7.11.1]
109572558  CSNK2A2; casein kinase II subunit alpha' isoform X1 [KO:K03097] [EC:2.7.11.1]
109577169  CSNK2B; casein kinase II subunit beta [KO:K03115]
109558922  CD4; T-cell surface glycoprotein CD4 [KO:K06454]
109572368  LCK; tyrosine-protein kinase Lck [KO:K05856] [EC:2.7.10.2]
109569940  CD3E; T-cell surface glycoprotein CD3 epsilon chain [KO:K06451]
109569992  CD3G; T-cell surface glycoprotein CD3 gamma chain [KO:K06452]
109577671  CD247; T-cell surface glycoprotein CD3 zeta chain isoform X1 [KO:K06453]
109569960  CD3D; T-cell surface glycoprotein CD3 delta chain [KO:K06450]
109565800  tyrosine-protein kinase ZAP-70 isoform X1 [KO:K07360] [EC:2.7.10.2]
109573385  MAP3K3; mitogen-activated protein kinase kinase kinase 3 isoform X1 [KO:K04421] [EC:2.7.11.25]
109574182  MAP2K3; dual specificity mitogen-activated protein kinase kinase 3 [KO:K04432] [EC:2.7.12.2]
109573853  MAP2K6; dual specificity mitogen-activated protein kinase kinase 6 isoform X1 [KO:K04433] [EC:2.7.12.2]
109577010  MAPK14; mitogen-activated protein kinase 14 isoform X1 [KO:K04441] [EC:2.7.11.24]
109577419  MAPK13; mitogen-activated protein kinase 13 [KO:K04441] [EC:2.7.11.24]
109578681  LAT; linker for activation of T-cells family member 1 isoform X1 [KO:K07362]
109567698  PLCG1; 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 [KO:K01116] [EC:3.1.4.11]
109563107  PPP3CC; serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform isoform X1 [KO:K04348] [EC:3.1.3.16]
109553732  PPP3CB; serine/threonine-protein phosphatase 2B catalytic subunit beta isoform isoform X1 [KO:K04348] [EC:3.1.3.16]
109560300  PPP3CA; serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform isoform X1 [KO:K04348] [EC:3.1.3.16]
109566227  PPP3R1; calcineurin subunit B type 1 [KO:K06268]
109563306  PPP3R2; calcineurin subunit B type 2 [KO:K06268]
109564913  RASGRP1; RAS guanyl-releasing protein 1 isoform X1 [KO:K04350]
109569809  CD28; T-cell-specific surface glycoprotein CD28 [KO:K06470]
109567889  PRKCQ; protein kinase C theta type [KO:K18052] [EC:2.7.11.13]
Compound
C00076  Calcium cation
C00165  Diacylglycerol
C01245  D-myo-Inositol 1,4,5-trisphosphate
C05981  Phosphatidylinositol-3,4,5-trisphosphate
Reference
  Authors
Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ
  Title
PD-L1.
  Journal
J Clin Pathol 71:189-194 (2018)
DOI:10.1136/jclinpath-2017-204853
Reference
  Authors
Zhou TC, Sankin AI, Porcelli SA, Perlin DS, Schoenberg MP, Zang X
  Title
A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
  Journal
Urol Oncol 35:14-20 (2017)
DOI:10.1016/j.urolonc.2016.10.004
Reference
  Authors
Wang Y, Wang H, Yao H, Li C, Fang JY, Xu J
  Title
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion.
  Journal
Front Pharmacol 9:536 (2018)
DOI:10.3389/fphar.2018.00536
Reference
  Authors
Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, Li Y, Li G, Xiong W, Guo C, Zeng Z
  Title
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
  Journal
Mol Cancer 18:10 (2019)
DOI:10.1186/s12943-018-0928-4
Reference
  Authors
Bardhan K, Anagnostou T, Boussiotis VA
  Title
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation.
  Journal
Front Immunol 7:550 (2016)
DOI:10.3389/fimmu.2016.00550
Reference
  Authors
Shi Y
  Title
Regulatory mechanisms of PD-L1 expression in cancer cells.
  Journal
Cancer Immunol Immunother 67:1481-1489 (2018)
DOI:10.1007/s00262-018-2226-9
Reference
  Authors
Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T
  Title
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.
  Journal
Oncogene 37:4639-4661 (2018)
DOI:10.1038/s41388-018-0303-3
Reference
  Authors
Chen J, Jiang CC, Jin L, Zhang XD
  Title
Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
  Journal
Ann Oncol 27:409-16 (2016)
DOI:10.1093/annonc/mdv615
Reference
  Authors
Glodde N, Holzel M
  Title
RAS and PD-L1: A Masters' Liaison in Cancer Immune Evasion.
  Journal
Immunity 47:1007-1009 (2017)
DOI:10.1016/j.immuni.2017.12.001
Reference
  Authors
Ritprajak P, Azuma M
  Title
Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma.
  Journal
Oral Oncol 51:221-8 (2015)
DOI:10.1016/j.oraloncology.2014.11.014
Reference
  Authors
Nirschl CJ, Drake CG
  Title
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy.
  Journal
Clin Cancer Res 19:4917-24 (2013)
DOI:10.1158/1078-0432.CCR-12-1972
Reference
  Authors
Saeidi A, Zandi K, Cheok YY, Saeidi H, Wong WF, Lee CYQ, Cheong HC, Yong YK, Larsson M, Shankar EM
  Title
T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses.
  Journal
Front Immunol 9:2569 (2018)
DOI:10.3389/fimmu.2018.02569
Reference
  Authors
Sharpe AH, Pauken KE
  Title
The diverse functions of the PD1 inhibitory pathway.
  Journal
Nat Rev Immunol 18:153-167 (2018)
DOI:10.1038/nri.2017.108
Reference
  Authors
Boussiotis VA
  Title
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
  Journal
N Engl J Med 375:1767-1778 (2016)
DOI:10.1056/NEJMra1514296
Reference
  Authors
Arasanz H, Gato-Canas M, Zuazo M, Ibanez-Vea M, Breckpot K, Kochan G, Escors D
  Title
PD1 signal transduction pathways in T cells.
  Journal
Oncotarget 8:51936-51945 (2017)
DOI:10.18632/oncotarget.17232
Reference
  Authors
Zuazo M, Gato-Canas M, Llorente N, Ibanez-Vea M, Arasanz H, Kochan G, Escors D
  Title
Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.
  Journal
Ann Transl Med 5:385 (2017)
DOI:10.21037/atm.2017.06.11
Reference
  Authors
Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA
  Title
PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2.
  Journal
Mol Cell Biol 33:3091-8 (2013)
DOI:10.1128/MCB.00319-13
Reference
  Authors
Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X
  Title
New immunotherapies targeting the PD-1 pathway.
  Journal
Trends Pharmacol Sci 36:587-95 (2015)
DOI:10.1016/j.tips.2015.06.005
Reference
  Authors
Ok CY, Young KH
  Title
Targeting the programmed death-1 pathway in lymphoid neoplasms.
  Journal
Cancer Treat Rev 54:99-109 (2017)
DOI:10.1016/j.ctrv.2017.01.009
Related
pathway
biu04010  MAPK signaling pathway
biu04020  Calcium signaling pathway
biu04066  HIF-1 signaling pathway
biu04151  PI3K-Akt signaling pathway
biu04514  Cell adhesion molecules
biu04620  Toll-like receptor signaling pathway
biu04660  T cell receptor signaling pathway
KO pathway
ko05235   
LinkDB

DBGET integrated database retrieval system